Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
Date
2019-04
Journal Title
Journal ISSN
Volume Title
Citation Stats
Attention Stats
Abstract
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Constantine, Gregory M, Peter B Bressler, Daniel Petroni, Dean D Metcalfe and Melody C Carter (2019). Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. The journal of allergy and clinical immunology. In practice, 7(4). pp. 1314–1316. 10.1016/j.jaip.2018.07.041 Retrieved from https://hdl.handle.net/10161/34834.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Peter Bartlett Bressler
Dr. Bressler has performed extensive research involving regulation of the immune system, He studied gene regulation of many different cytokines, NFKB and gene regulation in HIV infection, Other studies focused on development of gene therapy techniques for patients infected with HIV. After joining the faculty at Duke , Dr, Bressler has maintained an active clinical practice and is part of an extensive program for asthma education, He is on the Educational Committee of the American Academy of Allergy, Asthma and Immunology and has given many educational lectures on the treatment of asthma, He is also a member of the Duke Institutional Committee For Graduate Medical Education. He has published numerous articles in both the basic sciences and in clinical medicine.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.